Il 2024-02-05 19:21 Colla, Carlo ha scritto:
Buonasera,
Cosa ne dite dell’integratore palmitoiletanolamide (Pea) e sue applicazioni/effetti per l’autismo ? Qualcuno ne ha già sentito parlare ?
Grazie mille
Carlo
Nel 2021 è uscita una review che si puo’ leggere integralmente in rete Colizzi M, Bortoletto R, Costa R, Zoccante L. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence. Nutrients. 2021 Apr 18;13(4):1346. doi: 10.3390/nu13041346. PMID: 33919499; PMCID: PMC8073263. https://www.mdpi.com/2072-6643/13/4/1346 Copio dall’articolo quanto segue “ Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity. …. Limited research suggests that PEA supplementation reduces overall autism severity by improving language and social and nonsocial behaviors. Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation” Ci sono buone premesse per fare delle sperimentazioni nel campo dello spettro autistico. Una sperimentazione sta partendo all’Università di Udine a cura di Marco Colizzi "The Supplementation Therapy in Autism and Response to Treatment Study (START) December 15, 2023 updated by: University of Udine The Supplementation Therapy in Autism and Response to Treatment (START) Study" https://ichgcp.net/clinical-trials-registry/NCT06187090 Copio dal sito quanto segue "Through this study, we wish to evaluate: the ability of PEA to alleviate symptoms of psychic distress (i.e., anxiety and/or depression) in Level 1 autistic adults; the safety and tolerability of sustained intake of PEA in Level 1 autistic adults; and the biological basis of PEA functioning…... Volunteers who express an interest in the study and are identified as having Level 1 autistic individuals with comorbid anxiety and/or depressive symptoms by their clinical teams will be approached by study researchers and given a patient information sheet. Those who agree to take part in the study will be invited for a screening visit……. As the present study was designed to assess the effect of PEA on mentally fragile conditions with interference in the global functioning of autistic individuals, we will focus on subjects with severity level 1, more affected by depressive and anxious symptoms than autistic subjects with higher levels of impairment, requiring a prioritisation of these manifestations compared to core symptoms” La sperimentazione è ancora in fase di reclutamento per cui chi ha le caratteristiche richieste dalla sperimentazione (adulti con autismo di livello 1 con associati sintomi di ansia e/o depressione ) potrebbe candidarsi a partecipare rivolgendosi a [email protected] o [email protected] Daniela Mariani Cerati